Our Featured Experts

Robert Ferris, MD, PhD
Dr. Ferris on Pembrolizumab and Nivolumab in Head and Neck Cancer
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.
Joshua Richter, MD
Oncology Specialists
Publication Bottom Border
Border Publication
x